The president said the cost of the drug should be much lower for Americans once negotiations with Novo Nordisk had concluded.

The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat Type 2 diabetes ...

President Trump said he would lower the prices of popular weight-loss drugs, pressuring shares of drugmakers Novo Nordisk and ...

Novo Nordisk shares fell on Friday after Donald Trump vowed to sharply lower the price of its popular weight loss drug ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.” ...

By Stine Jacobsen and Bhanvi Satija COPENHAGEN (Reuters) -Shares of weight-loss drug makers Novo Nordisk and Eli Lilly fell ...

During a press conference, Trump specifically mentioned Ozempic, referring to it as "the fat loss drug" when asked about a $1 ...

On the face of it, the chances of success appear slim: the vast majority of experimental drugs for Alzheimer’s have ended in ...

Shares of Danish pharmaceutical giant Novo Nordisk are trading lower Friday morning, continuing an after-hours slide that ...

In a significant stride for chronic disease management, FDA granted approvals for Roche’s lupus nephritis treatment and Novo Nordisk’s cardiovascular-risk-reducing oral semaglutide for adults with ...

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss ...